These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
147 related articles for article (PubMed ID: 19389129)
1. A medical device/drug delivery system for treatment of glaucoma. Schultz CL; Poling TR; Mint JO Clin Exp Optom; 2009 Jul; 92(4):343-8. PubMed ID: 19389129 [TBL] [Abstract][Full Text] [Related]
2. Fixed combinations of dorzolamide-timolol and brimonidine-timolol in the management of glaucoma. Razeghinejad MR; Sawchyn AK; Katz LJ Expert Opin Pharmacother; 2010 Apr; 11(6):959-68. PubMed ID: 20307220 [TBL] [Abstract][Full Text] [Related]
3. A randomized, investigator-masked, 4-week study comparing timolol maleate 0.5%, brinzolamide 1%, and brimonidine tartrate 0.2% as adjunctive therapies to travoprost 0.004% in adults with primary open-angle glaucoma or ocular hypertension. Reis R; Queiroz CF; Santos LC; Avila MP; Magacho L Clin Ther; 2006 Apr; 28(4):552-9. PubMed ID: 16750466 [TBL] [Abstract][Full Text] [Related]
4. Glaucoma therapy by extended release of timolol from nanoparticle loaded silicone-hydrogel contact lenses. Jung HJ; Abou-Jaoude M; Carbia BE; Plummer C; Chauhan A J Control Release; 2013 Jan; 165(1):82-9. PubMed ID: 23123188 [TBL] [Abstract][Full Text] [Related]
5. Contact lenses as a drug delivery device for epidermal growth factor in the treatment of ocular wounds. Schultz CL; Morck DW Clin Exp Optom; 2010 Mar; 93(2):61-5. PubMed ID: 20406255 [TBL] [Abstract][Full Text] [Related]
6. Drug delivery by contact lens in spontaneously glaucomatous dogs. Peng CC; Ben-Shlomo A; Mackay EO; Plummer CE; Chauhan A Curr Eye Res; 2012 Mar; 37(3):204-11. PubMed ID: 22335807 [TBL] [Abstract][Full Text] [Related]
7. In vitro and in vivo evaluation of novel implantation technology in hydrogel contact lenses for controlled drug delivery. Maulvi FA; Lakdawala DH; Shaikh AA; Desai AR; Choksi HH; Vaidya RJ; Ranch KM; Koli AR; Vyas BA; Shah DO J Control Release; 2016 Mar; 226():47-56. PubMed ID: 26860285 [TBL] [Abstract][Full Text] [Related]
8. Extended drug delivery by contact lenses for glaucoma therapy. Peng CC; Burke MT; Carbia BE; Plummer C; Chauhan A J Control Release; 2012 Aug; 162(1):152-8. PubMed ID: 22721817 [TBL] [Abstract][Full Text] [Related]
9. Co-delivery of timolol and hyaluronic acid from semi-circular ring-implanted contact lenses for the treatment of glaucoma: in vitro and in vivo evaluation. Desai AR; Maulvi FA; Pandya MM; Ranch KM; Vyas BA; Shah SA; Shah DO Biomater Sci; 2018 May; 6(6):1580-1591. PubMed ID: 29708242 [TBL] [Abstract][Full Text] [Related]
10. Chick chorioallantoic membrane model for in ovo evaluation of timolol maleate-brimonidine tartrate ocular inserts. Ravindran VK; Repala S; Subadhra S; Appapurapu AK Drug Deliv; 2014 Jun; 21(4):307-14. PubMed ID: 24134746 [TBL] [Abstract][Full Text] [Related]
11. An eight-week, multicentric, randomized, interventional, open-label, phase 4, parallel comparison of the efficacy and tolerability of the fixed combination of timolol maleate 0.5%/brimonidine tartrate 0.2% versus fixed combination of timolol maleate 0.5%/dorzolamide 2% in patients with elevated intraocular pressure. Hatanaka M; Grigera DE; Barbosa WL; Jordao M; Susanna R J Glaucoma; 2008 Dec; 17(8):674-9. PubMed ID: 19092465 [TBL] [Abstract][Full Text] [Related]
12. Fixed-combination brimonidine-timolol versus latanoprost in glaucoma and ocular hypertension: a 12-week, randomized, comparison study. Katz LJ; Rauchman SH; Cottingham AJ; Simmons ST; Williams JM; Schiffman RM; Hollander DA Curr Med Res Opin; 2012 May; 28(5):781-8. PubMed ID: 22458918 [TBL] [Abstract][Full Text] [Related]
13. Risk factors for visual field progression in the low-pressure glaucoma treatment study. De Moraes CG; Liebmann JM; Greenfield DS; Gardiner SK; Ritch R; Krupin T; Am J Ophthalmol; 2012 Oct; 154(4):702-11. PubMed ID: 22835512 [TBL] [Abstract][Full Text] [Related]
14. Physicochemical and pharmacological investigation of water/oil microemulsion of non-selective beta blocker for treatment of glaucoma. Hegde RR; Bhattacharya SS; Verma A; Ghosh A Curr Eye Res; 2014 Feb; 39(2):155-63. PubMed ID: 24073659 [TBL] [Abstract][Full Text] [Related]
15. Development of brimonidine niosomes laden contact lenses for extended release and promising delivery system in glaucoma treatment. Tripathi S; Yadav KS Daru; 2024 Jun; 32(1):161-175. PubMed ID: 38158475 [TBL] [Abstract][Full Text] [Related]
16. Brimonidine: a new alpha2-adrenoreceptor agonist for glaucoma treatment. Greenfield DS; Liebmann JM; Ritch R J Glaucoma; 1997 Aug; 6(4):250-8. PubMed ID: 9264305 [TBL] [Abstract][Full Text] [Related]
17. Short-term tolerability of once-daily timolol hemihydrate 0.5%, timolol maleate in sorbate 0.5%, and generic timolol maleate gel-forming solution 0.5% in glaucoma and/or ocular hypertension: a prospective, randomized, double-masked, active-controlled, three-period crossover pilot study. Sonty S; Mundorf TK; Stewart JA; Stewart WC Clin Ther; 2009 Oct; 31(10):2063-71. PubMed ID: 19922877 [TBL] [Abstract][Full Text] [Related]
18. Co-Delivery of Timolol and Brimonidine with a Polymer Thin-Film Intraocular Device. Samy KE; Cao Y; Kim J; Konichi da Silva NR; Phone A; Bloomer MM; Bhisitkul RB; Desai TA J Ocul Pharmacol Ther; 2019 Mar; 35(2):124-131. PubMed ID: 30615539 [TBL] [Abstract][Full Text] [Related]
19. Diadenosine tetraphosphate improves adrenergic anti-glaucomatous drug delivery and efficiency. Loma P; Guzman-Aranguez A; Perez de Lara MJ; Pintor J Exp Eye Res; 2015 May; 134():141-7. PubMed ID: 25701803 [TBL] [Abstract][Full Text] [Related]
20. A randomized trial of brimonidine versus timolol in preserving visual function: results from the Low-Pressure Glaucoma Treatment Study. Krupin T; Liebmann JM; Greenfield DS; Ritch R; Gardiner S; Am J Ophthalmol; 2011 Apr; 151(4):671-81. PubMed ID: 21257146 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]